174 related articles for article (PubMed ID: 36965100)
21. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
[TBL] [Abstract][Full Text] [Related]
23. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy.
Li Q; Su R; Bao X; Cao K; Du Y; Wang N; Wang J; Xing F; Yan F; Huang K; Feng S
Acta Biomater; 2022 May; 144():109-120. PubMed ID: 35314366
[TBL] [Abstract][Full Text] [Related]
24. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
25. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Li C; Zhang N; Zhou J; Ding C; Jin Y; Cui X; Pu K; Zhu Y
Cancer Immunol Res; 2018 Feb; 6(2):178-188. PubMed ID: 29217732
[TBL] [Abstract][Full Text] [Related]
26. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
[TBL] [Abstract][Full Text] [Related]
27. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
28. A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response.
Zhu X; Wang X; Li B; Zhang Y; Chen Y; Zhang W; Wang Y; Zhai W; Liu Z; Liu S; Sun J; Chen Z; Gao Y
Small; 2022 May; 18(20):e2107001. PubMed ID: 35434938
[TBL] [Abstract][Full Text] [Related]
29. Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy.
Liu M; Cao Z; Zhang R; Chen Y; Yang X
ACS Appl Mater Interfaces; 2021 Jul; 13(29):33874-33884. PubMed ID: 34275267
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Tang T; Huang X; Zhang G; Lu M; Hong Z; Wang M; Huang J; Zhi X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288467
[TBL] [Abstract][Full Text] [Related]
31. Evoking tumor associated macrophages by mitochondria-targeted magnetothermal immunogenic cell death for cancer immunotherapy.
Jiang H; Fu H; Guo Y; Hu P; Shi J
Biomaterials; 2022 Oct; 289():121799. PubMed ID: 36152515
[TBL] [Abstract][Full Text] [Related]
32. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
Zhang S; Huang Y; Pi S; Chen H; Ye F; Wu C; Li L; Ye Q; Lin Y; Su Z
J Nanobiotechnology; 2023 Oct; 21(1):360. PubMed ID: 37789342
[TBL] [Abstract][Full Text] [Related]
33. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
34. Paraptosis Inducer to Effectively Trigger Immunogenic Cell Death for Metastatic Tumor Immunotherapy with IDO Inhibition.
Zheng RR; Zhao LP; Huang CY; Cheng H; Yang N; Chen ZX; Cai H; Zhang W; Kong RJ; Li SY
ACS Nano; 2023 Jun; 17(11):9972-9986. PubMed ID: 37200049
[TBL] [Abstract][Full Text] [Related]
35. Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.
Zhou Z; Liu Y; Song W; Jiang X; Deng Z; Xiong W; Shen J
J Control Release; 2022 Dec; 352():793-812. PubMed ID: 36343761
[TBL] [Abstract][Full Text] [Related]
36. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
37. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
Lu L; Zhang H; Zhou Y; Lin J; Gao W; Yang T; Jin J; Zhang L; Nagle DG; Zhang W; Wu Y; Chen H; Luan X
Theranostics; 2022; 12(7):3456-3473. PubMed ID: 35547769
[No Abstract] [Full Text] [Related]
38. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
39. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
40. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
